Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported a net operating cash outflow of US$77.8 million for the year ended December 31, 2025, as it increased spending across clinical, regulatory and manufacturing work to support its global pivotal PARADIGM trial.
The structural heart company said research and development expenses totalled US$69.1 million in 2025, reflecting manufacturing and quality scale-up work, higher R&D headcount, PARADIGM preparatory activities and clinical costs linked to enrolling additional patients, alongside expansion of its field-based clinical team and medical affairs activities.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) will present updated clinical data on its lead cell therapy program at one of the world’s largest healthcare investment forums next week, as the company continues to build international visibility around its immuno-oncology pipeline.
The clinical-stage biotech said chief medical officer Dr John Byon will present at the TD Cowen 46th Annual Health Care Conference in Boston at 1:10 pm ET on Monday, March 2, 2026.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has reported revenue of US$6.12 million for the six months to December 31, 2025 (1H FY26), down slightly from US$6.31 million a year earlier, as the company progressed multiple FebriDx commercial and regulatory milestones in the US.
Product sales rose, led by FebriDx, with sale of goods increasing to US$1.68 million from US$0.84 million in 1H FY25. Lumos said the uplift reflected an additional US$1.39 million in FebriDx revenue, more than offsetting the absence of US$0.65 million in discontinued ViraDx sales recorded in the prior period.
Auric Mining Ltd (ASX:AWJ) has produced 4,819oz of gold across three outturns from Campaign Two at its Munda Gold Mine Starter Pit, with a final outturn plus gold-in-circuit (GIC) still to be calculated.
The company reported the second outturn of 1,585oz was completed on February 17, 2026, followed by a third outturn of 2,087oz on February 26, 2026.
Ora Banda Mining Ltd (ASX:OBM, OTC:ESGFF) has reported record half-year revenue of $336.3 million for the six months to December 31, 2025, up 80% from $186.4 million in the prior corresponding period, supported by higher gold sales and a stronger realised gold price.
EBITDA increased 106% to $173.2 million, while EBIT rose 170% to $140.7 million and profit before tax lifted 176% to $140.1 million.
Noxopharm Ltd (ASX:NOX) has signed an At-the-Market Subscription Agreement (ATM) with Acuity Capital, providing access to up to $5 million in standby equity capital over a 5-year term to July 31, 2031.
Under the agreement, Noxopharm has full discretion over whether to draw on the facility, the maximum number of shares issued, the minimum issue price, and the timing of any subscriptions. The company is not required to use the ATM and can terminate it at any time without cost or penalty.
The Calmer Co International Ltd (ASX:CCO) has signed a 24-month Master Supply Agreement with a US-based functional beverage company to supply premium CO₂-extracted kava ingredients that is expected to deliver approximately $2 million in revenue per annum.
The agreement supports its B2B ingredients strategy and provides improved revenue visibility, with the contract structured around a quarterly supply framework aligned to the customer’s production planning.
Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) has once again delivered the numbers global markets were hoping for — and perhaps a little more.
The AI chip giant reported record fourth-quarter revenue of US$68.1 billion for the period ended January 25, 2026, up 20% on the previous quarter and 73% year-on-year. For the full fiscal year, revenue surged 65% to US$215.9 billion, underlining the scale of the AI infrastructure buildout now under way.
EcoGraf Ltd (ASX:EGR, OTCQX:ECGFF) has completed an updated bankable feasibility study (BFS) for its Epanko Graphite Project in Tanzania, outlining a 73,000-tonne-per-annum (tpa) operation with a pre-tax net present value (NPV10) of US$516 million and an internal rate of return of 31.1%.
The revised study increases planned throughput by 21.7% to 73,000 tpa for the first 15 years, supported by an updated ore reserve of 16.7 million tonnes at 8.2% total graphite carbon. Pre-production capital is estimated at US$181.2 million, with additional resettlement costs of US$18.1 million. Annual EBITDA is projected at US$85.7 million, based on a life-of-mine basket price of US$1,746 per tonne.
IDP Education shares rallied 12.6% in morning trade, ranking among the ASX 200's strongest performers, after the international student placement and English language testing company delivered a first-half earnings beat and raised its full-year outlook.
Shares are currently (12.30AEST) 13.94% higher to $5.23.
Cleanaway Waste Management shares jumped 8.3% after the waste services company delivered a modest first-half earnings beat and lifted its full-year outlook, with underlying strength across its core divisions offsetting a cluttered statutory result.
Underlying EBIT rose 16.9% to $228.2 million, nudging ahead of both RBC Capital Markets and consensus forecasts, driven by solid growth in the Solid Waste Services segment and a better-than-expected contribution from the recently acquired Contract Resources business. Net revenue climbed 13% to $1.875 billion, while underlying EBIT margin edged 40 basis points higher to 12.2%, reflecting price increases, labour efficiency gains, and the ongoing fleet transformation programme.
Qantas Airways (ASX:QAN) shares came under pressure after the airline delivered a mixed half-year result, with headline profit climbing 5.1% to $1.46 billion — marginally ahead of expectations — while underlying EBIT, net income, and the interim dividend of 19.8¢ all fell short of consensus.
The stock shed as much as 5.3% to its lowest level since mid-December, as investors struggled to look past the misses. IG market analyst Tony Sycamore warned that management commentary flagging rising airport charges, government fees, and broader cost pressures outpacing inflation has raised genuine questions about margin sustainability. "Qantas now appears poised to test key uptrend support near $10.00 before any stabilisation," he said.
Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO, FRA:1NOR) has secured firm commitments to raise about A$8.2 million, exceeding the A$6 million initially targeted earlier this week, as the gold explorer moves to accelerate drilling across its Western Australian and Victorian projects.
The company said it had received commitments for C$7.9 million (about A$8.2 million) through a placement of around 16.8 million units at C$0.10 per unit and about 61.1 million CHESS Depository Interests (CDIs) at A$0.105 per CDI to institutional, professional and sophisticated investors.
Marmota Ltd (ASX:MEU) has reported further wide, high-grade gold intercepts from its maiden drilling program at the Greenewood discovery in South Australia’s Gawler Craton, with the mineralised system now stretching around 900 metres and remaining open in all directions.
The latest Stage 2 reverse circulation (RC) results include intersections of up to 44 metres at 2.3 g/t gold from 16 metres downhole, including 4 metres at 16 g/t, and 36 metres at 3.0 g/t from 64 metres, including 4 metres at 18 g/t. Other standout results feature 32 metres at 3.2 g/t gold, including 4 metres at 24 g/t, and 20 metres at 4.3 g/t gold from 24 metres downhole.
Capral Ltd (ASX:CAA, FRA:CBZ) has reported audited FY25 results showing higher earnings and revenue despite softer volumes and subdued conditions across key end markets.
The aluminium extruder and distributor delivered revenue of $686 million for the 12 months to 31 December 2025, up 6% from $650 million in FY24. The increase was driven by higher average London Metal Exchange (LME) prices and an improved sales mix, offsetting a 4% decline in volumes to 65,000 tonnes (FY24: 67,800 tonnes).
Control Bionics Ltd (ASX:CBL)'s newly announced US joint venture with NextLevel Assistive Technology will enable it to scale into the largest segment of the American augmentative and alternative communication (AAC) market without taking on manufacturing risk. The United States has an estimated 2.5–3.5 million individuals requiring speech-generating solutions. Tablet-based devices, particularly those built on iOS platforms, now account for around 60–70% of new US SGD prescriptions. Annual US SGD volumes are estimated at 55,000–65,000 units, with iOS-based devices representing a US$100–150 million annual segment.
The company’s US subsidiary, Control Bionics Inc., has entered into an exclusive manufacturing, distribution and intellectual property licence agreement with NextLevel to commercialise a new range of Apple iOS-based speech generating devices (SGDs) in the United States.